On Jan. 11, 2021, Baxter announced an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M adjuvant.

The agreement was expected to advance commercial-scale manufacturing essential for the vaccine’s production and distribution in the United Kingdom and European markets.